Diaphragm dysfunction in chronic obstructive pulmonary disease: A role for heparan sulphate?

European Respiratory Journal

Volumn 30, Issue 1, 2007, Pages 80-89

  Ottenheijm, C A C ^a   Jenniskens, G J ^a   Geraedts, M C P ^a   Hafmans, T ^a   Heunks, L M A ^a,b   van Kuppevelt, T H ^a   Dekhuijzen, P N R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Diaphragm muscle; Glycosaminoglycan; Heparan sulphate

Indexed keywords

CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; SCATTER FACTOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DIAPHRAGM; DISEASE CLASSIFICATION; DOWN REGULATION; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; LUNG FUNCTION; MALE; MUSCLE BIOPSY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AGED; DIAPHRAGM; EPITOPES; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG DISEASES; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MUSCLE CONTRACTION; PEPTIDE LIBRARY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 34447561646     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00125106     Document Type: Article

References (45)

1. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003; 168: 10-48.
2. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 961-966.
3. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997; 337: 1799-1806.
4. Levine S, Nguyen T, Kaiser LR, et al. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 2003; 168: 706-713.
5. Orozco-Levi M, Lloreta J, Minguella J, Serrano S, Broquetas JM, Gea J. Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1734-1739.
6. Orozco-Levi M, Gea J, Lloreta JL, et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 371-378.
7. Mercadier JJ, Schwartz K, Schiaffino S, et al. Myosin heavy chain gene expression changes in the diaphragm of patients with chronic lung hyperinflation. Am J Physiol 1998; 274: L527-L534.
8. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 200-205.
9. Ottenheijm CA, Heunks LM, Hafmans T, et al. Titin and diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 527-534.
10. Ottenheijm CA, Heunks LM, Li YP, et al. Activation of ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 997-1002.
11. Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulphate. J Biol Chem 1998; 273: 24979-24982.
12. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003; 4: 926-937.
13. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005; 6: 646-656.
14. Jenniskens GJ, Veerkamp JH, Van Kuppevelt TH. Heparan sulphates in skeletal muscle development and physiology. J Cell Physiol 2006; 206: 283-294.
15. Habuchi H, Suzuki S, Saito T, et al. Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J 1992; 285: 805-813.
16. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulphate. J Biol Chem 1992; 267: 10337-10341.
17. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulphate. Elucidation of the major heparan sulphate structural determinants. J Biol Chem 1994; 269: 11216-11223.
18. Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulphate, and dermatan sulphate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 1994; 269: 20388-20393.
19. Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M. Characterization of heparin and heparan sulphate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem 1997; 272: 5518-5524.
20. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-β1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-β1. J Cell Physiol 1992; 152: 430-440.
21. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulphate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
22. Crisona NJ, Allen KD, Strohman RC. Muscle satellite cells from dystrophic (mdx) mice have elevated levels of heparan sulphate proteoglycan receptors for fibroblast growth factor. J Muscle Res Cell Motil 1998; 19: 43-51.
23. McFarland DC, Liu X, Velleman SG, Zeng C, Coy CS, Pesall JE. Variation in fibroblast growth factor response and heparan sulphate proteoglycan production in satellite cell populations. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134: 341-351.
24. Casar JC, Cabello-Verrugio C, Olguin H, Aldunate R, Inestrosa NC, Brandan E. Heparan sulphate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation. J Cell Sci 2004; 117: 73-84.
25. Van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. Generation and application of type-specific anti-heparan sulphate antibodies using phage display technology. Further evidence for heparan sulphate heterogeneity in the kidney. J Biol Chem 1998; 273: 12960-12966.
26. Van Kuppevelt TH, Jenniskens GJ, Veerkamp JH, ten Dam GB, Dennissen MA. Phage display technology to obtain antiheparan sulphate antibodies. Methods Mol Biol 2001; 171: 519-534.
27. Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, Van Kuppevelt TH. Heparan sulphate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J Neurosci 2000; 20: 4099-4111.
28. Smetsers TF, van de Westerlo EM, ten Dam GB, et al. Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J Invest Dermatol 2004; 122: 707-716.
29. Lensen JF, Wijnhoven TJ, Kuik LH, et al. Selection and characterization of a unique phage display-derived antibody against dermatan sulfate. Matrix Biol 2006; 25: 457-461.
30. Lensen JF, Rops AL, Wijnhoven TJ, et al. Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol 2005; 16: 1279-1288.
31. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
32. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
33. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-238.
34. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest 2001; 108: 169-173.
35. Conrad HE. Heparin-Binding Proteins. New York, Academic Press, 1998.
36. Jennische E, Ekberg S, Matejka GL. Expression of hepatocyte growth factor in growing and regenerating rat skeletal muscle. Am J Physiol 1993; 265: C122-C128.
37. Powell-Braxton L, Hollingshead P, Warburton C, et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993; 7: 2609-2617.
38. MacGowan NA, Evans KG, Road JD, Reid WD. Diaphragm injury in individuals with airflow obstruction. Am J Respir Crit Care Med 2001; 163: 1654-1659.
39. Nguyen T, Shrager J, Kaiser L, et al. Developmental myosin heavy chains in the adult human diaphragm: coexpression patterns and effect of COPD. J Appl Physiol 2000; 88: 1446-1456.
40. Lewis MI, Horvitz GD, Clemmons DR, Fournier M. Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. Am J Physiol Endocrinol Metab 2002; 282: E483-E490.
41. Petrini S, Tessa A, Carrozzo R, et al. Human melanoma/NG2 chondroitin sulphate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies. Mol Cell Neurosci 2003; 23: 219-231.
42. Barbosa I, Morin C, Garcia S, et al. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J Cell Sci 2005; 118: 253-264.
43. Gautron J, Kedzia C, Husmann I, Barritault D. [Acceleration of the regeneration of skeletal muscles in adult rats by dextran derivatives.]. C R Acad Sci III 1995-318: 671-676.
44. Zimowska M, Szczepankowska D, Streminska W, et al. Heparan sulphate mimetics modulate calpain activity during rat Soleus muscle regeneration. J Cell Physiol 2001; 188:178-187.
45. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 1999; 13: 761-766.